去纤苷(Defibrotide)正品有合适的购买方式吗？

Introduction: Defibrotide is used to treat adult and pediatric patients with hepatic veno-occlusive disease (VOD, also known as sinusoidal obstruction syndrome (SOS)), as well as patients with renal or pulmonary dysfunction after hematopoietic stem cell transplantation (HSCT). It should be noted that defibrotide is contraindicated in patients who are concurrently undergoing systemic anticoagulant therapy or fibrinolytic therapy, and those who are allergic to defibrotide or any of its excipients.

The appropriate way to purchase authentic Defibrotide

1. Hospital pharmacies: Defibrotide will be available in hospital pharmacies in listed countries. Patients can purchase it directly from the hospital pharmacy with a doctor's prescription after visiting the hospital.

2. Physical pharmacies: Some professional pharmacies or chain pharmacies in countries where defibrotide is listed may provide sales services for defibrotide. Patients can go to local pharmacies in the countries where defibrotide is listed to purchase. A medical prescription is usually required before purchasing.

3. Online pharmacies: Some legal online pharmacies in China may provide defibrinoside purchasing services. Patients can consult their customer service staff to learn more.

4. Drug suppliers: Some drug suppliers may sell defibrotide, and patients can learn about the purchasing process, price and other information by contacting the supplier.

Patients need to have a prescription issued by a doctor when purchasing, and ensure it is legal and reliable to avoid purchasing fake and shoddy products. At the same time, follow the instructions of your doctor or pharmacist to use the medicine correctly. During the treatment process, patients can maintain close contact with doctors and pharmacists to obtain more information about Defibrotide to obtain better treatment effects.

Precautions for Defibrotide

1. Bleeding: Defibrotide may increase the risk of bleeding in VOD patients after HSCT. Do not use Defibrotide in patients with active bleeding. Monitor patients taking defibrotide for signs of bleeding and suspend or discontinue use if bleeding occurs. Simultaneous systemic anticoagulation or fibrinolytic therapy may increase the risk of bleeding and should be discontinued before defibrotide treatment. Consider delaying the use of defibrotide until the effect of the anticoagulant weakens.

2. Hypersensitivity reactions: Less than 2% of patients treated with Defibrotide experienced allergic reactions, including rash, urticaria and angioedema. A case of allergic reaction was reported in a patient previously treated with Defibrotide. Monitor patients for allergic reactions, especially those with a history of exposure. If a severe allergic reaction occurs, discontinue defibrotide, treat according to standard of care, and monitor until symptoms subside.